SRT2104 (GSK2245840)|cas 1093403-33-8|DC Chemicals

SRT2104 (GSK2245840)|cas 1093403-33-8|DC Chemicals

SRT2104 (GSK2245840) is a selective SIRT1 activator involved in the regulation of energy homeostasis. Phase 2.

Product Name: SRT2104 (GSK2245840) |Catalog Number:  DC8412 | cas: 1093403-33-8 | Other names: GSK 2245840,GSK-2245840,GSK2245840,SRT-2104,SRT 2104 | Chemical name：4-methyl-N-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide | Molecule Formula: C26H24N6O2S2 | MW: 516.64

SRT2104 reduces p65/RelA acetylation levels in C2C12 cells.[1]In male C57BL/6J mice, SRT2104 (100 mg/kg, p.o.) extends both mean and maximal lifespan of mice fed a standard diet, and enhances motor coordination, bone mineral density, and insulin sensitivity and decreased inflammation. Short-term SRT2104 treatment preserves bone and muscle mass in an experimental model of atrophy.[1] In Male N171-82Q HD mice, SRT2104 (diet containing 0.5% SRT2104) effectively penetrates the blood-brain barrier, attenuates brain atrophy, improves motor function, and extends survival.

For research and scientific purpose only, not for human use.